One Year After Spike In American Deaths From China-sourced Contaminated Heparin, U.S. Pharmocopeia Issues Revised Standards
This article was originally published in PharmAsia News
Executive Summary
BEIJING - When heparin sourced from China mysteriously and suddenly began triggering a spike in extreme adverse reactions and deaths across American hospitals 18 months ago, U.S. FDA rapidly called on the U.S. Pharmacopeial Convention to help devise new testing methods to determine the purity and quality of the blood thinner
You may also be interested in...
After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
BEIJING - After signing an agreement on cooperation with China's Center for Disease Control and Prevention in the wake of a series of contaminated drug and food scandals, leaders of the U.S. Pharmacopeial Convention are working to develop new tests that could be used to safeguard the global supply chain
After Signing Pact With Chinese Regulators, U.S. Pharmacopeia Seeks To Develop New Tests To Help Prevent Deadly Episodes of Adulteration
BEIJING - After signing an agreement on cooperation with China's Center for Disease Control and Prevention in the wake of a series of contaminated drug and food scandals, leaders of the U.S. Pharmacopeial Convention are working to develop new tests that could be used to safeguard the global supply chain
U.S. Pharmacopeial Convention Signs Pact With Chinese Regulators To Strengthen Cooperation
BEIJING - In the latest advance in a two-year drive to step up cooperation with Chinese scientists and regulators - during a series of drug and food adulteration scandals that have claimed casualties across the Pacific - the U.S. Pharmacopeial Convention has signed a new agreement with China's Center for Disease Control and Prevention